Register now to R3i !
Your Login
Your Password
Confirm Password  
Your Email
R3i Activities Highlights
10 -12 june 2017, St Petersburg, Russia
MSDA 2017 - 12th Metabolic Syndrome, type II Diabetes and Atherosclerosis Congress
Read full report..
R3i editorial
28 July 2017

Prof. Jean Charles Fruchart, Prof. Michel Hermans, Prof. Pierre Amarenco
Targeting residual cardiovascular risk: lipids and beyond…Read more...

Accumulation of cholesterol from atherogenic apolipoprotein B-containing lipoproteins in the arterial wall has long been considered the instigator of atherosclerosis. As a result, preventive measures have focused on reducing levels of these atherogenic lipoproteins, with low-density lipoprotein cholesterol (LDL-C) the priority lipid target.
Add-on treatments, such as ezetimibe and the PCSK9 inhibitors, to standard of care therapy have been shown to reduce the residual risk of cardiovascular events in high risk patients; recent news from the REVEAL (Randomized EValuation of the Effects of Anacetrapib through Lipid modification) study provides further support for this strategy.
PCSK9 and Atherosclerosis
Downloadable slidekit
PCSK9 downloadable slidekit
Created by Professors Jean Davignon (Vice-President of the R3i foundation), Jean-Charles Fruchart (President of R3i) and Michel Hermans (R3i General Secretary), the latest downloadable deck of 242 slides discusses the potential role for anti-PCSK9 mAbs in the future management of cardiovascular disease.
landmark study
28 July 2017

EMPA-REG OUTCOME trial: Empagliflozin and cerebrovascular events Read more...

The EMPA-REG OUTCOME trial had previously shown that empagliflozin added to standard care in patients with type 2 diabetes and high cardiovascular risk, resulted in reduction in major adverse cardiovascular events. This finding was driven by reduction in cardiovascular mortality, with no significant difference between...
focus on...
28 July 2017

Novel therapeutics for managing elevated triglycerides by targeting angiopoietin-like 3 (ANGPTL3) Read more...

In June, the R3i website discussed a proof-of-concept study showing that ANGPTL3 deficiency is associated with lower triglycerides and LDL cholesterol, as well as protection from coronary artery disease (1). Following on from this, these two reports have provided additional evidence of the benefit of...
recent publication

**NEWS ALERT** CANTOS and REVEAL studies both meet the primary study endpointRead more...

(Canakinumab Anti-inflammatory Thrombosis Outcomes Study) showing that each study had met its primary endpoint (1,2).
 
On June 22, Novartis...
recent publication

EURIKA: Need to do better in managing atherogenic dyslipidaemia in primary preventionRead more...

According to the latest report from the EURIKA study, one in five patients without a history of cardiovascular events, have...
recent publication

TECOS: underachievement on targets in secondary prevention diabetes patientsRead more...

Action is needed to improve the care of type 2 diabetes patients with cardiovascular disease (CVD) to reduce their high...
recent publication

Alzheimer’s dementia linked with metabolic syndromeRead more...

This review highlights accumulating evidence which suggests a link between dysfunctional insulin signalling and glucose metabolism in the brain and...
recent publication

Is the ratio of Eicosapentaenoic Acid (EPA) to Arachidonic Acid a Residual Risk Marker?Read more...

Omega-3 polyunsaturated fatty acids (PUFAs) represent one therapeutic option for managing lipid-related residual cardiovascular risk. These treatments have a number...
recent publication

Are triglycerides causal in cardiovascular disease?Read more...

Insights from genetic studies have proved critical in investigating the causality of triglycerides in cardiovascular disease risk. This new review...

What is residual risk ?

Residual risk of vascular events persisting in patients at treatment goals according to current standards of care or failing to meet goals, including risk related to dyslipidemia, high blood pressure, hyperglycemia, systemic inflammation and unhealthy lifestyles.

What is the Initiative ?

The R3i, a worldwide, academic, multidisciplinary non-profit organization, aims to successfully address the excessively high risk of macro- and micro-vascular complications in patients with atherogenic dyslipidemia, characterised by elevated triglycerides and low levels of high-density lipoprotein (HDL) cholesterol and unaddressed by current standards of care.